AOM

AOM Therapeutics is a biotechnology company focused on developing first-in-class small molecule inhibitors targeting Protein Arginine Deiminase 4 (PAD4). The company's lead program, AOM-001, is being developed for the treatment of acute myeloid leukemia (AML) and other oncology indications where PAD4 plays a critical role in gene regulation and disease progression. By inhibiting PAD4, AOM Therapeutics aims to modulate the epigenetic landscape of cancer cells to induce differentiation and cell death. Beyond oncology, the company explores the potential of its PAD4 inhibitors in autoimmune and inflammatory conditions. AOM Therapeutics operates as a spin-off from academic research, leveraging deep expertise in chemical biology and medicinal chemistry.